CD8A and pancreatic adenocarcinoma: Cytotoxic CD8+ T-cell responses to mesothelin-derived epitopes restricted by human leukocyte antigens (HLA)-A2, A3 and A24 have been described in surgically treated patients with pancreatic adenocarcinoma who received granulocyte-macrophage colony-stimulating factor-immunotherapy [23].